The Chamber of Cannabis Industry Ghana (CannaCham) has welcomed recent executive action by the United States government to expand and prioritise scientific research into medical marijuana and cannabidiol (CBD), describing the move as a strong signal of growing global acceptance of cannabis for legitimate medical and industrial use.
In a policy statement, the Chamber said the U.S. decision reinforces an emerging international consensus that cannabis, when governed by rigorous, evidence-based regulation, can play a meaningful role in healthcare, research, and industrial development.
According to CannaCham, the U.S. action is particularly instructive for Ghana as it continues to operationalise its own medical and industrial cannabis framework under Legislative Instrument 2470 (LI 2470). The Chamber noted that expanded global research strengthens the case for Ghana to deepen scientific collaboration, strengthen regulatory standards, and support responsible private-sector participation across the cannabis value chain.
The Chamber reiterated its support for a strictly regulated, public-health-oriented cannabis industry, emphasising the importance of scientific research, clinical evidence, and compliance with international standards. It added that responsible development of the sector could unlock opportunities for value addition, export growth, job creation, and broader industrial development.
CannaCham also encouraged Ghanaian regulators, policymakers, and stakeholders to continue constructive engagement with industry players, research institutions, and international partners to ensure that Ghana remains competitive and compliant within the evolving global medical cannabis ecosystem.
The Chamber said it remains committed to supporting government and regulators through advocacy, capacity building, standards development, and international collaboration to promote the responsible growth of the cannabis industry in Ghana.
